ECSP22054700A - Derivados espiráncos sustituidos de cadena lineal - Google Patents

Derivados espiráncos sustituidos de cadena lineal

Info

Publication number
ECSP22054700A
ECSP22054700A ECSENADI202254700A ECDI202254700A ECSP22054700A EC SP22054700 A ECSP22054700 A EC SP22054700A EC SENADI202254700 A ECSENADI202254700 A EC SENADI202254700A EC DI202254700 A ECDI202254700 A EC DI202254700A EC SP22054700 A ECSP22054700 A EC SP22054700A
Authority
EC
Ecuador
Prior art keywords
spiranch
derivatives
linear chain
chain substituted
protein
Prior art date
Application number
ECSENADI202254700A
Other languages
English (en)
Inventor
Xiangjun Deng
Lichao Fang
Olivier Alexis Georges Querolle
Yanping Xu
Lianzhu Liu
Xuedong Dai
Nicolas Freddy J Darville
Johannes Wilhelmus John F Thuring
Alicia Tee Fuay Ng
Edward Cleator
Qiwu Zhao
Vineet Pande
William Maton
Gregor Thomas Urbanietz
Wei Cai
Ming Li
Kangying Li
Yingtao Liu
Liqiang Fu
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of ECSP22054700A publication Critical patent/ECSP22054700A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a agentes farmacéuticos útiles para la terapia y/o profilaxis en un mamífero, a una composición farmacéutica que comprende tales compuestos y a su uso como inhibidores de la interacción proteína/proteína de la menina/MLL, útiles para tratar enfermedades tales como el cáncer, que incluye, sin carácter limitante, leucemia, síndrome mielodisplásico (SMD) y neoplasias mieloproliferativas (NMP); y diabetes.
ECSENADI202254700A 2019-12-19 2022-07-12 Derivados espiráncos sustituidos de cadena lineal ECSP22054700A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019126760 2019-12-19
US202062961775P 2020-01-16 2020-01-16
CN2020126595 2020-11-04

Publications (1)

Publication Number Publication Date
ECSP22054700A true ECSP22054700A (es) 2022-11-30

Family

ID=76476870

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202254700A ECSP22054700A (es) 2019-12-19 2022-07-12 Derivados espiráncos sustituidos de cadena lineal

Country Status (21)

Country Link
US (1) US12473295B2 (es)
EP (1) EP4077312A4 (es)
JP (3) JP7554829B2 (es)
KR (1) KR20220118500A (es)
CN (4) CN118255773A (es)
AU (1) AU2020404305B2 (es)
CA (1) CA3161045A1 (es)
CL (3) CL2022001583A1 (es)
CO (1) CO2022009085A2 (es)
CR (1) CR20220346A (es)
DO (1) DOP2022000125A (es)
EC (1) ECSP22054700A (es)
IL (1) IL293965B1 (es)
JO (1) JOP20220154A1 (es)
MX (1) MX2022007652A (es)
PE (1) PE20230162A1 (es)
PH (1) PH12022551502A1 (es)
TW (2) TWI878414B (es)
UA (1) UA129208C2 (es)
UY (1) UY38988A (es)
WO (1) WO2021121327A1 (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3577109A4 (en) 2017-01-31 2020-11-18 Arvinas Operations, Inc. CEREMONY LIGANDS AND BIFUNCTIONAL COMPOUNDS CONTAINING THEM
TWI878414B (zh) 2019-12-19 2025-04-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
EP4077309A1 (en) 2019-12-19 2022-10-26 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of androgen receptor
WO2022237626A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
AU2022275192A1 (en) 2021-05-08 2024-01-04 Janssen Pharmaceutica Nv Substituted spiro derivatives
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
PH12023553300A1 (en) * 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
MX2024006783A (es) * 2021-12-03 2024-07-29 Bionova Pharmaceuticals Shanghai Ltd Compuestos de diazaspiro sustituidos con carbonilo y su uso.
WO2024046457A1 (en) * 2022-09-02 2024-03-07 Hutchmed Limited Triazine compounds and uses thereof
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer
TW202448429A (zh) 2023-04-17 2024-12-16 比利時商健生藥品公司 組合治療
CN122055156A (zh) 2023-10-20 2026-05-15 詹森药业有限公司 用于治疗癌症的(r)-n-乙基-5-氟-n-异丙基-2-((5-(2-(6-((2-甲氧基乙基)(甲基)氨基)-2-甲基-己-3-基)-2,6-二氮杂螺[3.4]辛-6-基)-1,2,4-三嗪-6-基)氧基)苯甲酰胺、其制剂和给药方案
CN120365200B (zh) * 2025-04-18 2025-11-11 北京蓝博特科技有限公司 一种(s)-2-(3,5-二甲基苯基)吡咯烷盐酸盐的制备方法

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2791732B2 (ja) 1992-04-02 1998-08-27 小野薬品工業株式会社 ３′−アミノ−２′−ヒドロキシアセトフェノンの製造方法
US6143749A (en) 1995-06-07 2000-11-07 Abbott Laboratories Heterocyclic substituted cyclopentane compounds
CA2476683C (en) 2002-02-19 2011-11-01 Cv Therapeutics, Inc. Partial and full agonists of a1 adenosine receptors
US20040043959A1 (en) 2002-03-04 2004-03-04 Bloom Laura A. Combination therapies for treating methylthioadenosine phosphorylase deficient cells
US20040138238A1 (en) 2002-08-08 2004-07-15 Dhanoa Dale S. Substituted aminopyrimidine compounds as neurokinin antagonists
JP4660199B2 (ja) 2002-12-23 2011-03-30 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 置換１−ピペリジン−４−イル−４−アゼチジン−３−イル−ピペラジン誘導体およびそれらのニューロキニン拮抗薬としての使用
US7612078B2 (en) 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
JP2007537296A (ja) 2004-05-14 2007-12-20 アボット・ラボラトリーズ 治療薬としてのキナーゼ阻害薬
EP1856128A4 (en) 2005-01-19 2009-12-23 Merck & Co Inc INHIBITORS OF MITOTIC KINESINE
GB0713602D0 (en) 2007-07-12 2007-08-22 Syngenta Participations Ag Chemical compounds
TWI389913B (zh) 2008-09-08 2013-03-21 Lg Life Sciences Ltd 并合雜環化合物
JP5343975B2 (ja) 2008-10-06 2013-11-13 日本電気株式会社 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム
WO2010066629A2 (en) 2008-12-09 2010-06-17 F. Hoffmann-La Roche Ag Novel azaindoles
JP2011026305A (ja) 2009-06-24 2011-02-10 Daiichi Sankyo Co Ltd イミダゾールカルボニル化合物を含有する医薬組成物
BR112012003870B1 (pt) 2009-08-20 2018-11-21 Bayer Intellectual Property Gmbh derivados de sulfeto substituídos com 3-triazolilfenila, seu uso, seu processo de preparação e seus intermediários, composições agroquímicas, seu processo de preparação, e processo para combate de parasitas animais
US8993552B2 (en) 2009-09-04 2015-03-31 The Regents Of The University Of Michigan Compositions and methods for treatment of leukemia
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
TW201204732A (en) 2010-07-09 2012-02-01 Leo Pharma As Novel homopiperazine derivatives as protein tyrosine kinase inhibitors and pharmaceutical use thereof
CA2819620A1 (en) 2010-12-03 2012-06-21 Epizyme, Inc. Modulators of histone methyltransferase, and methods of use thereof
AU2011336272A1 (en) 2010-12-03 2013-06-20 Epizyme, Inc. 7-deazapurine modulators of histone methyltransferase, and methods of use thereof
GB201021623D0 (en) 2010-12-21 2011-02-02 Isis Innovation Detection of acute myeloid leukaemia
EP2736901A1 (en) 2011-07-28 2014-06-04 Cellzome Limited Heterocyclyl pyrimidine analogues as jak inhibitors
CN103228195B (zh) 2011-08-01 2016-01-20 奥林巴斯株式会社 插入部形状估计装置
US9150574B2 (en) 2011-09-14 2015-10-06 Proximagen Limited Enzyme inhibitor compounds
WO2014035140A2 (en) 2012-08-30 2014-03-06 Kainos Medicine, Inc. Compounds and compositions for modulating histone methyltransferase activity
CN103664991B (zh) 2012-09-19 2016-12-28 中国科学院福建物质结构研究所 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途
MX2015006191A (es) 2012-11-16 2015-08-10 Merck Sharp & Dohme Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana.
US8993555B2 (en) 2012-12-21 2015-03-31 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9908887B2 (en) 2012-12-21 2018-03-06 Epizyme, Inc. PRMT5 inhibitors and uses thereof
US9745291B2 (en) 2012-12-21 2017-08-29 Epizyme, Inc. PRMT5 inhibitors containing a dihydro- or tetrahydroisoquinoline and uses thereof
US9216993B2 (en) 2013-03-13 2015-12-22 The Regents Of The University Of Michigan Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof
KR20160063366A (ko) 2013-10-21 2016-06-03 메르크 파텐트 게엠베하 Btk 저해제로서 헤테로아릴 화합물 및 이들의 용도
EP3139902A2 (en) 2014-05-06 2017-03-15 The Procter & Gamble Company Fragrance compositions
US20170119769A1 (en) 2014-06-10 2017-05-04 The Trustees Of The University Of Pennsylvania Scaffolds for inhibitors of menin-mll interactions
WO2015200680A2 (en) 2014-06-25 2015-12-30 Epizyme, Inc. Prmt5 inhibitors and uses thereof
CN105330698B (zh) 2014-07-04 2019-05-28 齐鲁制药有限公司 螺环芳基磷氧化物和硫化物
PL3165530T3 (pl) 2014-07-04 2019-07-31 Qilu Pharmaceutical Co., Ltd Spirocykliczny arylowy tlenek fosforu (V) i arylowy siarczek fosforu (V)
WO2016040330A1 (en) 2014-09-09 2016-03-17 The Regents Of The University Of Michigan Thienopyrimidine and thienopyridine compounds and methods of use thereof
GB201416352D0 (en) 2014-09-16 2014-10-29 Shire Internat Gmbh Spirocyclic derivatives
WO2016060941A1 (en) 2014-10-14 2016-04-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US10526341B2 (en) 2014-11-19 2020-01-07 Memorial Sloan-Kettering Cancer Center Thienopyrimidines and uses thereof
ES2788454T3 (es) 2014-12-18 2020-10-21 Takeda Pharmaceuticals Co Formas en estado sólido de pirrolidinonas heteroaromáticas condensadas
CN105732636B (zh) 2014-12-30 2020-04-21 广东东阳光药业有限公司 杂芳化合物及其在药物中的应用
EA031895B1 (ru) 2015-02-24 2019-03-29 Пфайзер Инк. Замещенные нуклеозидные производные, полезные в качестве агентов против рака
HK1246593A1 (zh) 2015-06-04 2018-09-14 Kura Oncology, Inc. 用於抑制menin蛋白与mll蛋白的相互作用的方法及组合物
AR104020A1 (es) 2015-06-04 2017-06-21 Kura Oncology Inc Métodos y composiciones para inhibir la interacción de menina con proteínas mill
TWI791251B (zh) 2015-08-26 2023-02-01 比利時商健生藥品公司 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物
CN108779116A (zh) 2015-12-22 2018-11-09 生命医药公司 多发性内分泌瘤蛋白-mll相互作用的抑制剂
EP3407884B1 (en) 2016-01-26 2025-07-09 Memorial Sloan-Kettering Cancer Center Targeting chromatin regulators for inhibiting leukemogenic gene expression in npm1
MX387806B (es) 2016-03-16 2025-03-19 Kura Oncology Inc Inhibidores biciclicos con puente sustituidos de menina-mll y metodos de uso
EP3429591B1 (en) 2016-03-16 2023-03-15 Kura Oncology, Inc. Substituted thieno[2,3-d]pyrimidine derivatives as inhibitors of menin-mll and methods of use
KR20190015275A (ko) 2016-05-02 2019-02-13 더 리젠츠 오브 더 유니버시티 오브 미시간 메닌 억제제로서의 피페리딘
WO2017207387A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction
KR102916887B1 (ko) 2016-06-10 2026-01-22 비타이 파마슈티컬즈, 엘엘씨 메닌-mll 상호 작용의 억제제
WO2018024602A1 (en) 2016-08-04 2018-02-08 Bayer Aktiengesellschaft 2,7-diazaspiro[4.4]nonanes
WO2018047598A1 (ja) 2016-09-06 2018-03-15 株式会社スリーボンド 熱硬化型導電性接着剤
TWI738864B (zh) 2016-09-14 2021-09-11 比利時商健生藥品公司 Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑
ES2872003T3 (es) 2016-09-14 2021-11-02 Janssen Pharmaceutica Nv Inhibidores espirobicíclicos de la interacción de menina-MLL
EP3512858B1 (en) 2016-09-14 2023-11-08 Janssen Pharmaceutica NV Fused bicyclic inhibitors of menin-mll interaction
US12084462B2 (en) 2016-09-14 2024-09-10 Janssen Pharmaceutica Nv Spiro bicyclic inhibitors of menin-MLL interaction
JP2019529421A (ja) 2016-09-16 2019-10-17 ヴァイティー ファーマシューティカルズ，エルエルシー ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤
WO2018106820A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
WO2018106818A1 (en) 2016-12-07 2018-06-14 Kura Oncology, Inc. Methods of promoting beta cell proliferation
KR102513564B1 (ko) 2016-12-15 2023-03-22 얀센 파마슈티카 엔.브이. 메닌-mll 상호작용의 아제판 억제제
EA201991448A1 (ru) 2017-01-06 2019-12-30 Янссен Фармацевтика Нв Азепановые ингибиторы взаимодействия менин-mll
CN108456208B (zh) 2017-02-22 2021-04-16 广州市恒诺康医药科技有限公司 氮杂螺环类化合物及其制备方法和应用
EP3601249A4 (en) 2017-03-24 2020-12-16 Kura Oncology, Inc. METHODS OF TREATMENT OF MALIGNANT HEMOPATHIES AND EWING'S SARCOMA
US11542248B2 (en) 2017-06-08 2023-01-03 Kura Oncology, Inc. Methods and compositions for inhibiting the interaction of menin with MLL proteins
AU2018283289B2 (en) 2017-06-16 2021-03-25 Beta Pharma, Inc. Pharmaceutical formulations of N-(2-(2-(dimethylamino)ethoxy)-4-methoxy-5-((4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide and salts thereof
WO2019012328A1 (en) 2017-07-09 2019-01-17 Biosight Pharma ANTICANCER POLY THERAPY
TW201920170A (zh) 2017-09-20 2019-06-01 美商庫拉腫瘤技術股份有限公司 經取代之menin-mll 抑制劑及使用方法
GB201720077D0 (en) 2017-12-01 2018-01-17 Univ Oxford Innovation Ltd Leukaemic stem cell
US11396517B1 (en) 2017-12-20 2022-07-26 Janssen Pharmaceutica Nv Exo-aza spiro inhibitors of menin-MLL interaction
JP7307729B2 (ja) 2017-12-20 2023-07-12 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ相互作用のエキソ－アザスピロ阻害剤
JP6671574B1 (ja) 2018-08-27 2020-03-25 大日本住友製薬株式会社 光学活性なアザビシクロ環誘導体
JP2022503792A (ja) 2018-09-26 2022-01-12 クラ オンコロジー，インク． メニン阻害剤を用いた血液悪性腫瘍の処置
MX2021006731A (es) 2018-12-07 2021-09-23 Univ Maryland Inhibidores de proteínas quinasas activadas por mitógeno p38 en sitio no atp/catalítico.
TW202104207A (zh) 2019-04-17 2021-02-01 美商健生生物科技公司 二氫乳清酸脫氫酶抑制劑
WO2020252229A2 (en) 2019-06-14 2020-12-17 Disarm Therapeutics, Inc. Inhibitors of sarm1
KR102924600B1 (ko) 2019-12-18 2026-02-09 솔루스첨단소재 주식회사 유기 화합물 및 이를 이용한 유기 전계 발광 소자
TWI878414B (zh) 2019-12-19 2025-04-01 比利時商健生藥品公司 經取代之直鏈螺環接衍生物
CN111297863B (zh) 2020-03-30 2021-06-25 四川大学华西医院 menin-MLL抑制剂在制备治疗子宫内膜癌的药物中的应用
WO2021207335A1 (en) 2020-04-07 2021-10-14 Syndax Pharmaceuticals, Inc. Combinations of menin inhibitors and cyp3a4 inhibitors and methods of use thereof
EP4253373A4 (en) 2020-11-30 2024-11-13 Astellas Pharma Inc. HETEROARYL CARBOXAMIDE COMPOUND
WO2022237626A1 (en) 2021-05-08 2022-11-17 Janssen Pharmaceutica Nv Substituted spiro derivatives
AU2022275192A1 (en) 2021-05-08 2024-01-04 Janssen Pharmaceutica Nv Substituted spiro derivatives
KR20240006638A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
KR20240006631A (ko) 2021-05-11 2024-01-15 얀센 파마슈티카 엔브이 조합 요법
JP2024520900A (ja) 2021-05-12 2024-05-27 シンダックス ファーマシューティカルズ， インコーポレイテッド 癌の治療のための組合せ
IL308862A (en) 2021-06-01 2024-01-01 Janssen Pharmaceutica Nv Altered phenyl-1H-pyrrolo[3,2-c]pyridine histories
BR112023025436A2 (pt) 2021-06-03 2024-02-27 Janssen Pharmaceutica Nv Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
PH12023553300A1 (en) 2021-06-17 2024-04-08 Janssen Pharmaceutica Nv (r)-n-ethyl-5-fluoro-n-isopropyl-2-((5-(2-(6-((2-methoxyethyl)(methyl)amino)-2-methylhexan-3-yl)-2,6-diazaspiro[3.4]octan-6-yl)-1,2,4-triazin-6-yl)oxy)benzamide besylate salt for the treatment of diseases such as cancer
MX2024006783A (es) * 2021-12-03 2024-07-29 Bionova Pharmaceuticals Shanghai Ltd Compuestos de diazaspiro sustituidos con carbonilo y su uso.
WO2023114867A2 (en) 2021-12-15 2023-06-22 Dana-Farber Cancer Institute, Inc. Therapeutic targeting of gastrointestinal stromal tumor (gist) by disrupting the menin-mll epigenetic complex
EP4472637A4 (en) * 2022-02-04 2025-12-31 Kura Oncology Inc TREATMENT OF HEMATOLOGICAL MALIGNITIES WITH MENNIN INHIBITORS AND P-GLYCOPROTEIN INHIBITORS
KR20250020447A (ko) 2022-05-09 2025-02-11 신닥스 파마슈티컬스, 인크. 암 치료를 위한 메닌-mll 억제제
JP2025540682A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． シクロブチル置換二環式化合物
WO2024114658A1 (en) 2022-11-30 2024-06-06 Janssen Pharmaceutica Nv Substituted 1-phenyl-3, 4-dihydropyrido [3, 4-d] pyrimidin-2-one derivatives
JP2025540762A (ja) 2022-11-30 2025-12-16 ヤンセン ファーマシューティカ エヌ．ベー． メニン－ｍｌｌ阻害剤及びｂｃｌ－２阻害剤を含む組み合わせ
EP4626426A1 (en) 2022-11-30 2025-10-08 JANSSEN Pharmaceutica NV Combinations comprising a menin-mll inhibitor and at least one other therapeutic agent
TW202448429A (zh) 2023-04-17 2024-12-16 比利時商健生藥品公司 組合治療

Also Published As

Publication number Publication date
US12473295B2 (en) 2025-11-18
KR20220118500A (ko) 2022-08-25
CL2023001530A1 (es) 2023-11-03
JP7554829B2 (ja) 2024-09-20
CR20220346A (es) 2022-10-26
PE20230162A1 (es) 2023-02-01
CO2022009085A2 (es) 2022-07-08
JP2023506530A (ja) 2023-02-16
AU2020404305A1 (en) 2022-08-04
TWI878414B (zh) 2025-04-01
JOP20220154A1 (ar) 2022-06-16
DOP2022000125A (es) 2022-08-31
JP2024138279A (ja) 2024-10-08
CL2022001583A1 (es) 2023-02-03
UY38988A (es) 2021-06-30
PH12022551502A1 (en) 2023-04-24
EP4077312A1 (en) 2022-10-26
CA3161045A1 (en) 2021-06-24
AU2020404305B2 (en) 2026-04-23
UA129208C2 (uk) 2025-02-05
JP2026035699A (ja) 2026-03-04
WO2021121327A1 (en) 2021-06-24
CN118344372A (zh) 2024-07-16
IL293965B1 (en) 2026-05-01
CL2023001531A1 (es) 2023-11-03
EP4077312A4 (en) 2024-01-17
CN114867721A (zh) 2022-08-05
TW202525813A (zh) 2025-07-01
TW202138367A (zh) 2021-10-16
CN118255774A (zh) 2024-06-28
MX2022007652A (es) 2022-09-23
IL293965A (en) 2022-08-01
JP7781961B2 (ja) 2025-12-08
CN118255773A (zh) 2024-06-28
US20230142285A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
DOP2022000125A (es) Derivados espiráncos sustituidos de cadena lineal
UY39795A (es) DERIVADOS DE FENIL-1H-PIRROLO[2,3-c]PIRIDINA SUSTITUIDOS
MX2019002959A (es) Inhibidores biciclicos condensados de la interaccion de menina-mll.
MX2019002962A (es) Inhibidores espirobiciclicos de la interaccion de menina-mll.
MX2021003939A (es) Inhibidores de la interaccion de menina-leucemia de linaje mixto.
EA201990699A1 (ru) Спиробициклические ингибиторы взаимодействия менин–mll
CL2018003577A1 (es) Piridina substituida como inhibidor de dnmt1.
MX2020006594A (es) Inhibidores de exo-azaespiro de la interaccion menina-mll.
CL2007002166A1 (es) Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer.
UY35293A (es) Isotiazoles sustituidos con amino
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
HN2003000162A (es) Derivados de isoindolona, proceso de preparacion y compuestos intermedios de este proceso, su uso como medicamentos, y composiciones farmaceuticas que los contienen.
MX2023013174A (es) Derivados espiro sustituidos.
MX2023013176A (es) Derivados espiro sustituidos.
CO2023018577A2 (es) Sal de besilato de (r)-n-etil-5-fluoro-n-isopropil-2-((5-(2-(6-((2-metoxietil)(metil)amino)-2-metilhexan-3-il)-2,6-diazaspiro[3.4]octan-6-il)-1,2,4-triazin-6-il)oxi)benzamida para el tratamiento de enfermedades tales como el cáncer
MX391405B (es) Inhibidores de azepano de la interacción menina-mll.
CL2016000024A1 (es) Volasertib en combinación con decitabina para el tratamiento de leucemia mieloide aguda y síndrome mielodisplásico.
BR112023025436A2 (pt) Piridazinas ou 1,2,4-triazinas substituídas por aminas espirocíclicas
CL2011000647A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores de enlace de la proteina smac al iap; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades proliferativas. (divisional de la solicitud 2234-2007).
CL2011000646A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; composicion farmaceutica que los comprende; util en el tratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
CL2011000645A1 (es) Compuestos derivados de heterociclos nitrogenados, inhibidores del enlace de la proteina smac al iap; y composicion farmaceutica que los comprende; y su uso en eltratamiento de enfermedades proliferativas. (divisional solicitud 2234-2007).
AR049380A1 (es) Mezclas fungicidas conteniendo derivados de triazolopirimidinas